Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection.
Yuan
P
P
Pharmacy Department, Clinical Center, NIH, Building 10, Room 1D51, 10 Center Drive, Bethesda, MD 20892-1196, USA.
Grimes
G J
GJ
Shankman
S E
SE
Daniels
C E
CE
Goldspiel
B R
BR
Potti
G K
GK
D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000032:analysis*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000032:analysis*; D004317:Doxorubicin / Q000008:administration & dosage* / Q000032:analysis*; D004344:Drug Incompatibility; D004349:Drug Packaging; D004355:Drug Stability; D004359:Drug Therapy, Combination / Q000032:analysis*; D005047:Etoposide / Q000008:administration & dosage* / Q000032:analysis*; D006863:Hydrogen-Ion Concentration; D008027:Light; D019999:Pharmaceutical Solutions; D012965:Sodium Chloride; D013696:Temperature; D014750:Vincristine / Q000008:administration & dosage* / Q000032:analysis*
D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D019999:Pharmaceutical Solutions; D012965:Sodium Chloride; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin